These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22194934)

  • 21. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
    Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
    Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
    Suh DJ; Um SH; Herrmann E; Kim JH; Lee YS; Lee HJ; Lee MS; Lee YJ; Bao W; Lopez P; Lee HC; Avila C; Zeuzem S
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1242-7. PubMed ID: 20028815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China].
    Shi KQ; Zhang DZ; Guo SH; He H; Wang ZY; Shi XF; Zeng WQ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2008 Sep; 16(9):641-5. PubMed ID: 18822200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of telbivudine treatment on the circulating CD4⁺ T-cell subpopulations in chronic hepatitis B patients.
    Zheng Y; Huang Z; Chen X; Tian Y; Tang J; Zhang Y; Zhang X; Zhou J; Mao Q; Ni B; Wang Q; Wu Y
    Mediators Inflamm; 2012; 2012():789859. PubMed ID: 22570512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B.
    Gu Y; Lian Y; Zheng Q; Huang Z; Gu L; Bi Y; Li J; Huang Y; Wu Y; Chen L; Huang Y
    BMC Infect Dis; 2020 Jul; 20(1):509. PubMed ID: 32664850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].
    Huang J; Chen XP; Chen XF; Chen WL; Chen R; Ma XJ; Luo XD
    Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):178-81. PubMed ID: 21586234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
    Chan HL; Heathcote EJ; Marcellin P; Lai CL; Cho M; Moon YM; Chao YC; Myers RP; Minuk GY; Jeffers L; Sievert W; Bzowej N; Harb G; Kaiser R; Qiao XJ; Brown NA;
    Ann Intern Med; 2007 Dec; 147(11):745-54. PubMed ID: 17909201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients].
    Zhang LJ; Wang L
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):561-3. PubMed ID: 19719910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection.
    Li Y; Ma S; Tang L; Li Y; Wang W; Huang X; Lai Q; Zhang M; Sun J; Li CK; Abbott WG; Naoumov NV; Zhang Y; Hou J
    Hepatology; 2013 Oct; 58(4):1277-86. PubMed ID: 23703545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.
    Gane EJ; Wang Y; Liaw YF; Hou J; Thongsawat S; Wan M; Moon YM; Jia J; Chao YC; Niu J; Leung N; Samuel D; Hsu CW; Bao W; Lopez P; Avila C
    Liver Int; 2011 May; 31(5):676-84. PubMed ID: 21457439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restoration of CD3
    Yu X; Zheng Y; Huang R; Dai X; Kang G; Wang X; Yan G; Ding B; Zheng M; Xu Y; Zong L
    Eur J Immunol; 2024 Aug; 54(8):e2451046. PubMed ID: 38778501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Telbivudine treatment on cirrhosis resulting from chronic hepatitis B].
    Liang J; Han T; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):24-7. PubMed ID: 19203447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses.
    Hann HW
    Expert Opin Pharmacother; 2010 Sep; 11(13):2243-9. PubMed ID: 20698726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roles of the programmed cell death 1, T cell immunoglobulin mucin-3, and cluster of differentiation 288 pathways in the low reactivity of invariant natural killer T cells after chronic hepatitis B virus infection.
    Yang Z; Lei Y; Chen C; Ren H; Shi T
    Arch Virol; 2015 Oct; 160(10):2535-45. PubMed ID: 26215444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional restoration of CD56
    Chen T; Zhu L; Shi A; Ding L; Zhang X; Tan Z; Guo W; Yan W; Han M; Jia J; Luo X; Schuppan D; Ning Q
    Hepatol Int; 2017 Sep; 11(5):419-428. PubMed ID: 28639033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
    Zhang Y; Hu P; Qi X; Ren H; Mao RC; Zhang JM
    Clin Microbiol Infect; 2016 Mar; 22(3):287.e1-9. PubMed ID: 26548508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a therapy].
    Luo XD; Chen XP; Chen XF
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):583-588. PubMed ID: 29056007
    [No Abstract]   [Full Text] [Related]  

  • 40. The serum interleukin-26 level is a potential biomarker for chronical hepatitis B.
    Luo L; Jiang L; Tian Z; Zhang X
    Medicine (Baltimore); 2020 Jan; 99(1):e18462. PubMed ID: 31895778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.